In Vitro Permeability and Transporter Studies
Autoimmune diseases and inflammation are complex conditions that pose significant challenges in drug and therapy development. Understanding the permeability and transport of drugs across biological barriers is crucial in optimizing therapeutic approaches. Our company, a leader in the field of pharmaceutical research and development, offers comprehensive in vitro permeability and transporter study services.
Introduction to In Vitro Permeability
In vitro permeability studies involve evaluating the ability of drugs to cross biological barriers, such as cell monolayers or artificial membranes, under controlled laboratory conditions. These studies provide essential information on drug absorption and bioavailability. Permeability assays measure the rate at which a drug molecule passes through the barrier and provide valuable data on its ability to reach its target site in the body.
Introduction to In Vitro Transporter
In vitro transporter studies focus on understanding the role of transporters in drug absorption, distribution, and elimination. Transporters are proteins that facilitate the movement of drugs across cell membranes, influencing their pharmacokinetics and therapeutic efficacy. These studies help identify drug-drug interactions, such as P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and breast cancer resistance protein (BCRP).
Fig. 1 Summary of examples of transporter-mediated drug-drug interaction (DDI) physiologically-based pharmacokinetic analyses. (Taskar K.S., et al., 2020)
In Vitro Permeability and Transporter Study for Autoimmune Diseases and Inflammation
Autoimmune diseases and inflammation are characterized by dysregulated immune responses, leading to tissue damage and organ dysfunction. Understanding the permeability and transport of drugs in these conditions is crucial for developing effective therapies. In vitro permeability and transporter studies help identify the barriers that limit drug absorption and distribution in autoimmune diseases. By assessing the permeability of drugs across inflamed tissues, researchers can gain insights into the efficacy of drug delivery. Additionally, In vitro transporter studies aid in understanding the impact of transporters on drug disposition in the context of inflammation.
Fig. 2 P-gp, MRP, BCRP in immune diseases. (Wu Y., et al., 2018)
Our Services
Our company offers a comprehensive range of in vitro permeability and transporter study services tailored to the specific needs of autoimmune disease and inflammation research. Our team of highly skilled scientists and technicians utilize cutting-edge techniques and equipment to provide accurate and reliable data.
| Permeability Studies | |
|---|---|
| Caco-2 permeability | MDCK-MDR1 permeability |
| Parallel artificial membrane permeability assay (PAMPA) | |
| Substrate Identification and Inhibition assays | |
| P-gp | BCRP |
| Human MRP transporter | |
| Preclinical hepatic Oatp uptake transporter (dog Oatp1b4, rat Oatp1b2 and Cynomolgus monkey Oatp1b1) | |
| Human SLC transporter ( OATP1A2, OATP2B1, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, OAT2, OAT4, OCTN2, PEPT1, PEPT2, MATE1, MATE2-K, NTCP) | |
| Using HEK293 cells transiently transfected with a single human transporter | |
| Vesicular transport assays for efflux transporter inhibition | |
Why Choose Us?
High Data Quality
Professional Team
One-stop Platform
Cost and Efficiency
As a research service provider, we recognize that each research project is unique, and we tailor our services to meet specific requirements. Our flexible approach allows for customized study designs, ensuring that researchers receive the most relevant and meaningful data for their investigations. If you are interested in our services, please don't hesitate to contact us.
References
- Taskar, Kunal S., et al. "Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future opportunities, and recommendations." Clinical Pharmacology & Therapeutics 107.5 (2020): 1082-1115.
- Wu, Yi-jin, Chun Wang, and Wei Wei. "The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases." Biomedicine & Pharmacotherapy 105 (2018): 870-878.